Skip to main content
Premium Trial:

Request an Annual Quote

Funding Update: NSF Grants Awarded to PhasiQ, Purdue


Recent NSF Awards in Proteomics and Protein Research

Title: Crosstalk-Free Multiplexed Immunoassay of Plasma Biomarkers
Principal Investigator: Arlyne Simon
Sponsor: PhasiQ
Start/End Date: July 1, 2013 – Dec. 31, 2013
Amount Awarded to Date: $149,715

Funds research into a device that can detect protein biomarkers in biological fluids via immunoassays while eliminating false positive signals from nonspecific binding. Also funds development of an initial test panel of protein markers for cardiovascular disease management and drug development.

Title: Gas-Phase Ion Chemistry of Peptide Radical Ions and Applications in Protein Characterization
Principal Investigator: Yu Xia
Sponsor: Purdue University
Start/End Date: July 1, 2013 – June 30, 2016
Amount Awarded to Date: $248,982

Funds research into new mass spectrometry methods and instrumentation for creating peptide radical ions in gas-phase and analyzing their chemical properties.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.